查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924708

猴痘抗体检测试剂市场按检测类型、技术平台、检体类型、最终用户、应用和销售管道划分－2026-2032年全球预测

Monkeypox Antibody Test Reagent Market by Test Type, Technology Platform, Sample Type, End User, Application, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，猴痘抗体检测试剂市场价值将达到 1.5353 亿美元，到 2026 年将成长至 1.7434 亿美元，到 2032 年将达到 3.3513 亿美元，复合年增长率为 11.79%。

关键市场统计数据
基准年 2025 1.5353亿美元
预计年份：2026年 1.7434亿美元
预测年份 2032 3.3513亿美元
复合年增长率 (%) 11.79%

一份全面的执行简报，重点阐述了猴痘抗体检测试剂对临床、监测和调查相关人员的策略重要性。

本执行摘要为诊断、临床护理、公共卫生和研究机构的领导者提供关于猴痘抗体检测试剂的策略指南，这些试剂是为猴痘检测和监测而开发的。随着临床需求的恢復、监测优先顺序的提高以及对检测特异性和安全性的日益重视，市场格局正在迅速变化。从检测设计到分销，对试剂开发过程的分析重点阐述了影响其在不同环境中应用的技术和商业性因素。

变革性变化正在推动跨平台、抗体标靶、监测重点和照护现场扩展的检测开发和部署。

猴痘抗体试剂领域正经历着变革性的转变，这重塑了研发、检验和部署的优先事项。技术革新是其核心。化学和检测方法的进步正在缩小实验室级检测与快速现场部署解决方案之间的差距。改进的抗原设计和增强的讯号放大提高了痘病毒抗体阳性检测的特异性，而样本处理的改进则降低了分析前变异性。因此，相关人员越来越能够权衡通量、灵敏度和操作简便性之间的利弊。

评估美国于2025年宣布的关税对试剂采购、生产经济和分销网络的累积影响

美国2025年前后的关税政策趋势为猴痘抗体检测试剂采购领域的相关人员带来了新的挑战。对进口原料、成品试剂和辅助组件征收的关税措施可能会改变生产商和采购商的经济考量，影响他们是否选择将生产迁回国内或继续依赖现有国际供应商。在此背景下，各组织必须重新评估筹资策略，以确保供应的连续性，同时控制单位成本并履行合约义务。

从详细的细分观点揭示测试类型、平台、检体基质、产品形式、应用、最终用户和销售管道如何影响试剂需求。

对市场区隔进行细緻分析，可以揭示技术和商业性决策如何影响试剂性能和市场定位。根据检测类型，检测 IgA、IgG、IgM 和总抗体的检测方法需要不同的抗原呈现和检验策略，以确保特异性和有意义的临床解释。急性感染检测与先前感染检测的性能特征取决于这些抗体标靶的选择和优化。

影响美洲、欧洲、中东和非洲以及亚太市场试剂采用和供应链韧性的区域趋势

区域趋势对试剂供应、监管预期和实施路径有显着影响。在美洲，许多公共卫生机构和大型医院系统优先考虑与实验室资讯系统快速集成，寻求明确的性能证据，并评估能够支持临床诊断和大规模血清流行病学调查的多方相关人员采购模式。因此，在该地区运营的製造商和经销商通常会优先考虑合规性、强大的客户支援和可扩展的物流解决方案。

竞争考察聚焦于创新蓝图、生产规模、监管策略、伙伴关係模式和差异化的商业性策略。

竞争考察揭示了决定抗体试剂领域成功与否的几个通用策略主题。首先，优先考虑高特异性抗原、简化工作流程以及与多种检体基质相容性的创新蓝图，能够为在不同环境下运作的客户创造永续价值。其次，生产规模和垂直整合决定了企业满足需求高峰和提供理想前置作业时间的能力，因此与契约製造工厂合作是扩大产能的常用途径。

为优化研发重点、增强供应链韧性以及加速临床和公共卫生领域的应用，提供实际的策略建议。

产业领导者应采取切实可行的优先行动方案，以巩固市场地位并支持公共卫生目标。首先，投资于跨平台相容性将使CLIA认证系统、ELISA平台和侧向层析检验试剂能够以模组化解决方案的形式交付，从而满足不同终端用户的需求。这种柔软性将减轻买方负担，并支援在中心检查室和分散式环境中同时部署。

一套严谨的调查方法，阐述了初级和次级资料收集、检测检验、相关人员访谈以及三角测量技术。

本执行摘要的调查方法结合了多种资料收集和检验技术，以确保其相关性和严谨性。关键资料来源包括对实验室主任、医院采购人员、公共卫生专案经理和检测方法开发人员进行结构化访谈，以了解营运限制、采购惯例和绩效预期。这些访谈旨在识别实施过程中的实际障碍，并挖掘临床诊断、流行病学监测、研究和疫苗开发等领域的真实应用案例。

简要结论总结了主要发现、对相关人员的策略意义以及试剂创新和部署的未来优先事项。

本概要总结了影响猴痘抗体试剂生态系统的关键驱动因素，并概述了对製造商、经销商和机构采购者的战略意义。 CLIA、ELISA 和侧向层析平台的技术进步正在拓展实际应用环境的范围，而监管机构持续强调严格的检验，确保检测能够满足临床和流行病学需求。受关税政策影响的生产规模、分销网络和供应链韧性仍然是保障供应和控製成本的关键因素。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：猴痘抗体检测试剂市场（依检测类型划分）

  • IgA
  • IgG
  • IgM

9. 依技术平台分類的猴痘抗体检测试剂市场

  • CLIA
  • ELISA
  • 快速交叉流法
    • 胶体金
    • 萤光法

第十章：依检体类型分類的猴痘抗体检测试剂市场

  • 电浆
  • 血清
  • 全血

第十一章 猴痘抗体检测试剂市场（依最终用户划分）

  • 诊断检查室
  • 医院
  • 公共卫生检查室
  • 研究所

第十二章：猴痘抗体检测试剂市场（依应用领域划分）

  • 临床诊断
  • 流行病学监测
  • 研究
  • 疫苗研发

第十三章 猴痘抗体检测试剂市场（依销售管道划分）

  • 离线
  • 在线的

第十四章 猴痘抗体检测试剂市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 猴痘抗体检测试剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国猴痘抗体检测试剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国猴痘抗体检测试剂市场

第十八章：中国猴痘抗体检测试剂市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AdvaCare Pharma Pvt. Ltd.
  • Applied DNA Clinical Labs, Inc.
  • Becton, Dickinson and Company
  • CerTest Biotec SL
  • FineTest International Co., Ltd.
  • Hangzhou AllTest Biotech Co., Ltd.
  • JOYSBIO Biotechnology Co., Ltd.
  • Laboratory Corporation of America Holdings
  • Mylab Discovery Solutions Pvt. Ltd.
  • Quest Diagnostics Incorporated
  • RayBiotech, Inc.
  • Roche Diagnostics GmbH
  • Sansure Biotech Inc.
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Vitrosens Diagnostics Pvt. Ltd.
Product Code: MRR-7A380DA7C43F

The Monkeypox Antibody Test Reagent Market was valued at USD 153.53 million in 2025 and is projected to grow to USD 174.34 million in 2026, with a CAGR of 11.79%, reaching USD 335.13 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.53 million
Estimated Year [2026] USD 174.34 million
Forecast Year [2032] USD 335.13 million
CAGR (%) 11.79%

Comprehensive executive overview highlighting the strategic importance of monkeypox antibody test reagents for clinical, surveillance, and research stakeholders

This executive summary provides a strategic orientation to antibody test reagents developed for monkeypox detection and surveillance, intended for leaders across diagnostics, clinical care, public health, and research organizations. The landscape has evolved rapidly, driven by renewed clinical demand, heightened surveillance priorities, and an intensified focus on assay specificity and safety. Examining reagent development from assay design through distribution reveals both technical and commercial levers that influence adoption across diverse settings.

The purpose of this document is to synthesize the most relevant developments and to clarify decision points for stakeholders who must balance clinical performance with operational feasibility. It highlights the interplay between assay biology, platform selection, sample handling, and end-user requirements, and it underscores the importance of aligning product formats with procurement channels and regulatory expectations. Furthermore, the summary emphasizes how diagnostic needs differ between centralized laboratories and point-of-care environments, and why those differences matter for reagent formulation and packaging.

Readers will find concise analyses of shifting dynamics, segmentation-driven implications, regional considerations, and concrete actions that manufacturers, distributors, and institutional buyers can take. Throughout the summary, attention is given to the practical constraints and opportunities that shape reagent availability, assay reliability, and the integration of antibody testing into clinical and public-health workflows.

Transformational changes driving assay development and deployment across platforms, antibody targets, surveillance priorities, and point of care expansion

The landscape for monkeypox antibody reagents is experiencing transformative shifts that are reshaping priorities across development, validation, and deployment. Technological evolution is central: advances in chemistries and detection modalities are narrowing the gap between laboratory-grade assays and rapid, field-deployable solutions. Improved antigen design and enhanced signal amplification have bolstered assay specificity for orthopoxvirus antibodies, and concurrent refinements in sample processing have reduced pre-analytical variability. As a result, stakeholders are increasingly able to weigh trade-offs between throughput, sensitivity, and operational simplicity.

Regulatory and reimbursement pathways are adapting in parallel, with agencies emphasizing robust validation datasets and post-market surveillance to ensure performance in diverse populations. This regulatory emphasis is prompting manufacturers to invest earlier in multicenter validation and to design assays that accommodate different sample types and workflows. At the same time, the public-health imperative for seroprevalence and contact-tracing studies is accelerating demand for scalable formats that can be deployed in both clinical laboratories and community settings.

Market dynamics are also influenced by supply chain considerations and the need for manufacturing redundancy. Strategic partnerships between assay developers, contract manufacturers, and distribution networks are becoming more common as a way to de-risk supply while enabling rapid scale-up when needed. Finally, integration with digital reporting platforms and laboratory information systems is emerging as a differentiator that enhances epidemiological utility and accelerates clinical adoption. Taken together, these shifts are driving a more integrated, resilient, and performance-focused reagent ecosystem.

Evaluating the cumulative implications of United States tariff actions announced for 2025 on reagent sourcing, manufacturing economics, and distribution networks

Recent tariff developments in the United States for 2025 have introduced a new layer of complexity for stakeholders involved in sourcing monkeypox antibody test reagents. Tariff measures that apply to imported raw materials, finished reagents, and ancillary components alter the economic calculus for manufacturers and buyers, and they can influence decisions about onshoring production versus continuing to rely on established international suppliers. In this environment, organizations must reassess procurement strategies to ensure continuity of supply while managing unit costs and contractual obligations.

Tariffs tend to have asymmetric effects across product formats: bulk reagents that are shipped in large volumes and rely on high-throughput production inputs can experience significant cost pressure, whereas compact kit formats intended for point-of-care use are often subject to different tariff classifications and logistical considerations. Consequently, some manufacturers may shift to localized fill-and-finish operations or seek tariff-exempt pathways, while distributors and end users reassess vendor contracts and consider alternative sourcing arrangements. Such adjustments can affect lead times, packing configurations, and minimum order quantities.

From a downstream perspective, public-health laboratories and hospital systems that rely on predictable reagent supply for surveillance and routine testing must incorporate tariff-induced variability into inventory planning and contracting. At the same time, novel procurement strategies-such as multi-year supply agreements, diversified distributor networks, and collaborative purchasing consortia-are practical responses that can mitigate disruption. Ultimately, effective management of tariff impacts requires proactive cross-functional coordination among regulatory, procurement, and supply chain teams to preserve assay performance and accessibility.

Granular segmentation perspectives revealing how test types, platforms, sample matrices, product formats, applications, end users, and sales channels shape reagent demand

A nuanced view of segmentation reveals how technical and commercial decisions influence reagent performance and market positioning. Based on test type, distinctions among IgA, IgG, IgM, and assays that measure total antibody require different antigen presentations and validation strategies to ensure specificity and meaningful clinical interpretation. Performance characteristics for acute infection detection versus historical exposure rely on the selection and optimization of these antibody targets.

Based on technology platform, each analytical approach brings distinct advantages and constraints: CLIA-grade platforms deliver high-throughput, centralized diagnostics suitable for laboratory workflows; ELISA formats provide quantitative readouts that support epidemiological surveys and research applications; and rapid lateral flow assays offer the speed and simplicity needed for point-of-care screening, with subvariants such as colloidal gold and fluorescent readers creating further performance and cost trade-offs. Based on end user, diagnostic laboratories and hospitals prioritize batch processing and traceability, public health laboratories require scalability for surveillance and contact tracing, and research institutes often demand flexibility for exploratory studies.

Based on sample type, reagent chemistry must be compatible with plasma, serum, or whole blood matrices, as pre-analytical conditions vary across collection settings. Based on product format, choices between bulk reagent and finished kits affect storage, distribution, and on-site handling. Based on application, differentiation among clinical diagnosis, epidemiological surveillance, research, and vaccine development informs performance targets, with clinical diagnosis subdivided into central lab and point of care, and epidemiological surveillance subdivided into contact tracing studies and seroprevalence surveys. Finally, based on sales channel, strategies range from direct sales-via government and private contracts-to distribution models with national or regional partners and online sales channels, each shaping commercial cadence and customer support expectations.

Regional dynamics shaping reagent adoption and supply chain resilience across the Americas, Europe Middle East & Africa, and Asia Pacific markets

Regional dynamics exert a strong influence on reagent availability, regulatory expectations, and adoption pathways. In the Americas, many public-health agencies and large hospital systems emphasize rapid integration with laboratory information systems, demand clear performance evidence, and value multi-stakeholder procurement approaches that can support both clinical diagnosis and large-scale seroprevalence studies. Consequently, manufacturers and distributors operating in this region often prioritize regulatory alignment, robust customer support, and scalable logistics solutions.

In Europe, Middle East & Africa, regulatory fragmentation and diverse infrastructure profiles require adaptable product strategies and flexible distribution models. Several countries prioritize centralized laboratory networks while others need point-of-care solutions for remote settings; therefore, suppliers must offer a portfolio that spans CLIA-equivalent platforms, ELISA kits, and robust lateral flow devices. Additionally, capacity building and technical transfer initiatives often accompany reagent deployment to ensure sustainable use.

In Asia-Pacific, the combination of advanced manufacturing capacity and significant public-health program activity creates both competition and collaboration opportunities. High-volume procurement programs, regional manufacturing hubs, and well-established contract manufacturing organizations support rapid scale-up, whereas heterogeneity in regulatory pathways and varying clinical practices mean that tailored validation packages and localized technical support are essential. Across all regions, resilience in the supply chain, clarity on customs and import requirements, and rapid response capabilities are decisive factors affecting adoption.

Competitive company insights focused on innovation roadmaps, manufacturing scale, regulatory strategies, partnership models, and differentiated commercial approaches

Competitive company insights point to several recurring strategic themes that influence who succeeds in the antibody reagent segment. First, innovation roadmaps that prioritize high-specificity antigens, simplified workflows, and compatibility with multiple sample matrices create enduring value for customers who must operate across diverse settings. Second, manufacturing scale and vertical integration often determine the ability to meet surge demand and to offer favorable lead times, making partnerships with contract manufacturers a common avenue for capacity expansion.

Regulatory strategy is another differentiator: companies that invest early in harmonized validation studies and maintain clear documentation for cross-border regulatory submissions reduce time-to-adoption and lower friction in procurement processes. Partnership models-whether through co-development with academic centers, distribution agreements with regional players, or collaborations with digital-health vendors-extend market reach and can accelerate integration into clinical and public-health workflows.

Commercial approaches that combine direct contracting with government agencies, targeted distributor relationships, and selective online offerings enable firms to balance scale with localized service. Leaders also emphasize post-market surveillance, customer training, and technical support as mechanisms to preserve product reputation and to gather real-world performance data that can inform iterative improvements. In sum, companies that align innovation, scale, regulatory foresight, and channel strategy are best positioned to capture long-term relevance in the reagent space.

Actionable strategic recommendations to optimize research and development focus, strengthen supply chain resilience, and speed clinical and public health adoption

Industry leaders should pursue a set of pragmatic, prioritized actions to strengthen market position and to support public-health goals. First, invest in cross-platform compatibility so that reagents validated on CLIA-grade systems, ELISA platforms, and lateral flow formats can be offered as modular solutions that meet diverse end-user needs. Such flexibility reduces friction for buyers and supports simultaneous deployment in central labs and decentralized settings.

Second, accelerate partnerships that expand manufacturing redundancy and local fill-and-finish capabilities to mitigate tariff and logistics risk. Complementary measures include establishing multi-year contracting arrangements with key buyers and implementing inventory strategies that account for lead-time variability. Third, prioritize validation studies that reflect real-world sample types-plasma, serum, and whole blood-and clearly document performance for both acute diagnosis and serological surveillance use cases.

Fourth, tailor commercial engagement to the sales channel: bespoke support models for government contracts, tiered service offerings for national and regional distributors, and streamlined online procurement for smaller institutions. Fifth, integrate digital reporting and quality-control solutions to enhance epidemiological value and customer trust. Finally, embed post-market surveillance and customer feedback loops into product lifecycles to enable rapid iteration and to address emerging variant or cross-reactivity concerns. Together, these steps will help organizations balance innovation, reliability, and responsiveness.

Robust research methodology explaining primary and secondary data collection, assay validation checks, stakeholder interviews, and triangulation methods

The research methodology underpinning this executive summary combines multiple data collection and validation techniques to ensure relevance and rigor. Primary inputs included structured interviews with laboratory directors, hospital procurement leads, public-health program managers, and assay developers to capture operational constraints, procurement practices, and performance expectations. These interviews were designed to identify practical barriers to adoption and to surface real-world use cases across clinical diagnosis, epidemiological surveillance, research, and vaccine development.

Secondary research involved a systematic review of technical literature, regulatory guidance, laboratory standards, and publicly available validation reports to contextualize assay performance claims and to understand cross-reactivity and matrix effects. Where possible, assay validation approaches were compared against established performance frameworks to evaluate claims around sensitivity, specificity, and reproducibility. Data triangulation was applied to reconcile differing accounts and to highlight robust patterns that emerged across sources.

Analytical steps included mapping segmentation dimensions against end-user requirements, assessing supply chain vulnerabilities, and synthesizing company strategies. Limitations of the methodology are acknowledged; for example, proprietary performance data and commercially confidential procurement terms are not publicly accessible. Nevertheless, the combination of stakeholder interviews, technical review, and cross-checking produced a coherent set of insights tailored to operational decision-makers.

Concise conclusion synthesizing key findings, strategic implications for stakeholders, and the forward-looking priorities for reagent innovation and deployment

This summary synthesizes the key drivers shaping the monkeypox antibody reagent ecosystem and outlines strategic implications for manufacturers, distributors, and institutional buyers. Technological progress across CLIA, ELISA, and lateral flow platforms is expanding the range of viable deployment settings, while ongoing regulatory emphasis on rigorous validation ensures assays meet clinical and epidemiological needs. Supply chain resiliency, influenced by manufacturing scale, distributor networks, and tariff dynamics, remains a practical determinant of availability and cost management.

Segmentation matters: differences in test type, platform, sample matrix, and product format create distinct value propositions that must be matched to end-user workflows and procurement channels. Regional constraints and opportunities further modulate adoption, with each geography requiring tailored validation, distribution, and support strategies. Companies that align innovation roadmaps with robust manufacturing and regulatory planning, and that leverage targeted commercial channels, will be best positioned to support both immediate clinical demands and long-term surveillance objectives.

In closing, the path forward requires coordinated efforts across R&D, manufacturing, and commercial teams, combined with proactive engagement with public-health stakeholders. By adopting flexible product portfolios, strengthening supply chain redundancy, and emphasizing real-world performance evidence, organizations can ensure that antibody testing contributes meaningfully to clinical care and population health goals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Monkeypox Antibody Test Reagent Market, by Test Type

  • 8.1. Iga
  • 8.2. Igg
  • 8.3. Igm

9. Monkeypox Antibody Test Reagent Market, by Technology Platform

  • 9.1. Clia
  • 9.2. Elisa
  • 9.3. Rapid Lateral Flow
    • 9.3.1. Colloidal Gold
    • 9.3.2. Fluorescent

10. Monkeypox Antibody Test Reagent Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Serum
  • 10.3. Whole Blood

11. Monkeypox Antibody Test Reagent Market, by End User

  • 11.1. Diagnostic Laboratory
  • 11.2. Hospital
  • 11.3. Public Health Laboratory
  • 11.4. Research Institute

12. Monkeypox Antibody Test Reagent Market, by Application

  • 12.1. Clinical Diagnosis
  • 12.2. Epidemiological Surveillance
  • 12.3. Research
  • 12.4. Vaccine Development

13. Monkeypox Antibody Test Reagent Market, by Sales Channel

  • 13.1. Offline
  • 13.2. Online

14. Monkeypox Antibody Test Reagent Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Monkeypox Antibody Test Reagent Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Monkeypox Antibody Test Reagent Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Monkeypox Antibody Test Reagent Market

18. China Monkeypox Antibody Test Reagent Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AdvaCare Pharma Pvt. Ltd.
  • 19.6. Applied DNA Clinical Labs, Inc.
  • 19.7. Becton, Dickinson and Company
  • 19.8. CerTest Biotec S.L.
  • 19.9. FineTest International Co., Ltd.
  • 19.10. Hangzhou AllTest Biotech Co., Ltd.
  • 19.11. JOYSBIO Biotechnology Co., Ltd.
  • 19.12. Laboratory Corporation of America Holdings
  • 19.13. Mylab Discovery Solutions Pvt. Ltd.
  • 19.14. Quest Diagnostics Incorporated
  • 19.15. RayBiotech, Inc.
  • 19.16. Roche Diagnostics GmbH
  • 19.17. Sansure Biotech Inc.
  • 19.18. Siemens Healthineers AG
  • 19.19. Sino Biological Inc.
  • 19.20. Vitrosens Diagnostics Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY FLUORESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY FLUORESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY FLUORESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PUBLIC HEALTH LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PUBLIC HEALTH LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PUBLIC HEALTH LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 173. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 181. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 182. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)